Table 1.

Overview of study findings related to safety and efficacy.

Condition	Efficacy Summary	Safety Summary	Dosing Ranges
CNS-Related Signs	24 of 36 studies reported positive findings (improvement in depressive symptoms) with SAMe There was a significant placebo effect overall—several studies found similar improvement with an SSRI, placebo, or SAMe 2	Case reports (n = 5): severe adverse events associated with SAMe use 1 Comparator-based studies (n = 18): typically did not find any significant difference in safety outcomes Most common adverse events were GI-related symptoms	Range: 200–3200 mg SAMe/day Many dose ranges titrated to 1600–3200 mg SAMe/day Usually in divided doses Often in combination with existing antidepressant regimen

¹ The case reports did not use a Naranjo scale or other validated assessments to examine the likelihood of the cause and effect. ² This indicates the variability of assessing change in depressive symptoms.